Predictors of Kidney Damage in Patients with Metabolic Syndrome

Supplementary Files

Correlation between hydrogen sulfid and microalbuminuria


metabolic syndrome
kidney damage
hydrogen sulfide

How to Cite

Kutsyk, D., & Sklyarov, E. (2017). Predictors of Kidney Damage in Patients with Metabolic Syndrome. Galician Medical Journal, 24(2).


Metabolic syndrome is an epidemic of XXI century. Each of the components of metabolic syndrome (arterial hypertension, hyperglycemia or dyslipidemia) can be a risk factor for chronic kidney disease. However, it remains unknown what plays a key role in the progression of the disease.

The objective of the research was to identify early detectors of kidney damage in patients with metabolic syndrome.

Materials and methods. The study involved 70 patients with metabolic syndrome. In addition to standard examination methods, markers of endothelial disfunction (hydrogen sulfide and nitrogen monooxide) were measured in venous blood samples and the urine was tested for microalbuminuria. All the patients were divided into 3 groups according to the degree of albuminuria: normoalbuminuria, microalbuminuria and macroalbuminuria. To compare the indices between the groups, the Student’s t-test was used; to determine the relationship between the individual values, the Pearson correlation coefficient (r) was applied.

Results. The indicator of systolic blood pressure was higher in patients with microalbuminuria compared to those with normoalbuminuria (163.4±14.4 mmHg, versus 153.0±17.7 mmHg; p<0.01). Hydrogen sulfide level was higher in patients with normoalbuminuria (66.8±7.2 µmol). There was a moderate positive correlation between systolic blood pressure and microalbuminuria (r=0.3804; p<0.01) and a moderate negative correlation between hydrogen sulfide and microalbuminuria (r=0.3404; p<0.01).

Conclusions. We revealed a decrease in hydrogen sulfide level to 57.4±7.9 µmol in patients with metabolic syndrome. This may be an early predictor of kidney damage.


Bailey R, Wang Y, Zhu V, Rupnow M. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;2; 407-415. doi: 10.1186/175605007415.

Beltowski J. Hydrogen sulfide in pharmacology and medicine - An update. Pharmacol Rep .2015 67(3): 647-658. doi: 10.1016/j.pharep.2015.01.005.

Bełtowski J. Hypoxia in the Renal Medulla: Implications for Hydrogen Sulfide Signaling. J Pharmacol Exp Ther. 2010;334(2):358-363. doi: 10.1124/jpet.110.166637.

Flannigan KL, Wallace JL. Hydrogen sulfide-based anti-inflammatory and chemopreventive therapies: an experimental approach. Curr Pharm Des. 2015;21(21):3012-3022 .

Ghigliotti G, Barisione C, Garibaldi S, Fabbi P, Brunelli C, Spallarossa P, Altieri P, Rosa G, Spinella G, Palombo D, Arsenescu R, Arsenescu V. Adipose Tissue Immune Response: Novel Triggers and Consequences for Chronic Inflammatory Conditions. Inflammation. 2014;37(4):1337-1353. doi: 10.1007/s1075301499141.

Hidzynska IM, Moroz HZ, Lasytsia TS, Bezuhla MV. Metabolichnyi syndrom ta sertsevo-sudynnyi ryzyk: suchasnyi pohliad na problemu. Arterialna hipertenziia. 2012;2(3). Available from:

Kaur M, Sachdeva S, Bedi O, Kaur T, Kumar P. Combined effect of hydrogen sulphide donor and losartan in experimental diabetic nephropathy in rats. J Diabetes Metab Disord. 2015; 22;14:80. doi: 10.1186/s40200-015-0212-8.

Kovalenko VM, Talayeva TV, Kozliuk AS. Metabolic syndrome: mechanisms, value as a predictor of cardiovascular diseases, approaches in diagnosis and treatment Ukraiinskyi kardiolohichnyi zhurnal. 2012;5;81-85.

Maiko O.V. Early diagnosis of chronic renal failure. Visnyk Vinnytskoho natsionalnoho medychnoho universytetu. 2015;19(1);263-265. [published in Ukrainian]

Nagpure BV, Bian JS. Interaction of Hydrogen Sulfide with nitric Oxide in the Cardiovascular system. Oxid Med Cell Longev. 2016; doi: 10.1155/2016/6904327.

Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014;18(7):421-435. doi: 10.2147/DMSO.S45183.

Prasad GV. Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol. 2016;3(4):210-219. doi: 10.5527/wjn.v3.i4.210.

Rojas E, Velasco M, Bermúdez V, Israili Z, Bolli P. Targeting Hypertension in Patients With Cardio-Renal Metabolic Syndrome. Curr Hypertens Rep. 2012;14(5): 397-402. doi: 10.1007/s11906-012-02925.

Van den Born JC, Frenay AR, Bakker SJ, Pasch A, Hillebrands JL, Lambers Heerspink HJ, van Goor H. High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes. Nitric Oxide. 2016;55-56:18-24. doi: 10.1016/j.niox.2016.03.001.

Zaichko NV, Pentyuk NO, Pentyuk LO, Melnyk AV, Andrushko II. Determination of hydrogen sulfide in blood serum. Visnyk naukovykh doslidzhen. 2009;1(54):29-32. [published in Ukrainian]

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.